DEFA14A: Champions Oncology Sets Annual Meeting for Oct 2025
Notice of Annual Meeting
Champions Oncology, Inc. announces its Annual Meeting of Stockholders for October 16, 2025, to address director elections, auditor ratification, and executive compensation.
Summary
- The Annual Meeting of Stockholders for Champions Oncology, Inc. is scheduled for October 16, 2025, at 9:00 a.m. local time at One University Plaza, Suite 307, Hackensack, New Jersey 07601.
- Stockholders will vote on three key proposals: the election of seven Board of Director nominees, the ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026, and a non-binding advisory resolution on executive officer compensation.
- Proxy materials are available online, and stockholders can request paper copies free of charge before September 30, 2025.
- The deadline for entering voting instructions is 11:59 p.m. Eastern Time on October 15, 2025.
- The record date for determining stockholders entitled to vote at the meeting is the close of business on August 22, 2025.
Sentiment
Score: 5
Explanation: This is a standard procedural filing for an annual meeting notice, containing no specific positive or negative financial or operational news that would impact sentiment.
Positives
- The Board of Directors recommends voting for all proposals, indicating unified management support for the proposed actions.
Future Outlook
No specific forward-looking statements or guidance regarding financial performance or strategic direction are provided in this notice.
Management Comments
- The Board of Directors recommends that you vote for all proposals.
Industry Context
This filing is a standard procedural notice for a public company's annual meeting, aligning with typical corporate governance practices and regulatory requirements for soliciting shareholder votes on routine matters.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Proposed Election | Proposal to elect seven Board of Director nominees for the ensuing year. | October 16, 2025 (upon election) | Ensures continuity or refreshment of board leadership and oversight. |
| Proposed Ratification | Proposal to ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026. | Fiscal year ending April 30, 2026 | Confirms the independent auditor for financial statement review and compliance. |
| Advisory Vote | Proposal to approve a non-binding advisory resolution relating to the compensation of named executive officers. | N/A (advisory) | Provides stockholders with an opportunity to express their views on executive compensation practices. |
Stakeholder Impact
- Shareholders: Provided with notice and access to materials to vote on key corporate governance matters, including director elections, auditor appointment, and executive compensation.
Next Steps
- Stockholders are encouraged to access and review the complete proxy materials online.
- Stockholders should submit their voting instructions by the specified deadline.
- The Annual Meeting will convene on October 16, 2025, to address the proposed agenda items.
Key Dates
| Date | Description |
|---|---|
| August 22, 2025 | Record date for stockholders entitled to receive notice of the Annual Meeting and to vote. |
| September 30, 2025 | Deadline to request paper copies of proxy materials. |
| October 15, 2025 | Deadline for entering voting instructions (11:59 p.m. Eastern Time). |
| October 16, 2025 | Annual Meeting of Stockholders at 9:00 a.m. local time. |
Recommendation
holdThis filing is a standard notice for an annual meeting, outlining procedural matters such as director elections, auditor ratification, and an advisory vote on executive compensation. It does not contain any new financial results, strategic updates, or operational performance metrics that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as there is no new information to alter an existing investment thesis.
Keywords
Champions Oncology, Annual Meeting, Proxy Statement, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, DEFA14A
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.